Table 1.

Baseline characteristics of patients with CD and UC.

	Total (n = 149)	CD (n = 82)	UC (n = 67)
Median age (years, IQR)	31.5 (24.0-47.3)	28.0 (21.0-33.0)	46.0 (29.0-49.0)
Median disease duration (years, IQR)	3.0 (1.0-4.0)	3.0(1.0-4.0)	3.0 (0.5-4.0)
Gender (%)
Male	100 (67.11)	56 (68.29)	44 (65.67)
Female	49 (32.89)	26 (31.71)	23 (34.33)
Smoking history (%)
Yes	10 (6.71)	3 (3.66)	7 (10.45)
No	139 (93.29)	79 (96.34)	60 (89.55)
CD location (%)
Ileal (L1)	19 (12.67)	19 (22.90)	—
Colonic (L2)	18 (12.00)	18 (21.69)	—
Ileocolonic (L3)	44 (29.53)	44 (53.65)	—
Upper gastrointestinal involvement (L4)	1(0.67)	1(1.22)	—
UC extent (Montreal) (%)
Proctitis (E1)	9 (6.00)	—	9 (13.43)
Left-sided (E2)	15 (10.00)	—	15 (22.39)
Extensive (E3)	43 (28.67)	—	43 (64.18)
Medication
None	12 (8.00)	9 (10.84)	3 (4.48)
5-ASA	96 (64.43)	34 (41.46)	62 (92.54)
Steroids	32 (21.33)	14 (16.87)	18 (26.87)
Thiopurine	15 (10)	13 (15.67)	2 (2.99)
Anti-TNF	46 (30.67)	43 (51.80)	3 (4.48)